Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

76 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-23

Study Completion Date

2024-05-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess health and quality of life outcomes in patients treated with benralizumab, within a Belgian Real-World setting. To prove the clinical value of benralizumab in a Real-World setting, the study will document the effect of benralizumab within a time frame of 112 weeks after initiation of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Non-interventional, Prospective Study With Benralizumab

NCT06422078

Asthma, Bronchial

RECRUITING

Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions

NCT04184284

Asthma

COMPLETED

Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.

NCT03833141

Severe Eosinophilic Asthma

COMPLETED

Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain

NCT04126499

Severe Eosinophilic Asthma

COMPLETED

Real World Study With Benralizumab in Severe Asthma in Switzerland

NCT03907137

Severe Eosinophilic Asthma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim and objective of this single arm, prospective observational study is to provide supporting RWE on the symptom relief of asthma patients qualified for benralizumab therapy in Belgium. The PRO measures consist of the Asthma Control Questionnaire (ACQ 6) as well as Patient Global Impression of Change and Severity (PGI-C and PGI-S), healthcare resource utilization (HCRU) and treatment satisfaction (TSQM-9). In addition change in daily OCS use and rate of exacerbations after initiation of benralizumab in real-world setting will be assessed

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients 18 years or older with physician's confirmed diagnosis of severe, uncontrolled asthma
* Asthma requiring high dose inhaled corticosteroid plus long-acting β adrenoceptor agonist as maintenance treatment
* A decreased lung function (FEV1 \<80%), demonstrated by spirometry in the 12 months before initiation of treatment
* Patients need to fulfil one of the criteria:

* at least 2 hospitalizations or ER treatments for severe asthma during last 12 months, or
* at least 2 asthma exacerbations during last 12 months (worsening of asthma with need of systemic corticotherapy for at least 3 days for non cortico-dependent patients, and/or an ER visit and or a hospitalization),
* or cortico-dependent (at least 6 months treatment with OCS at a daily dose of 4 mg or more of methylprednisolone or 5 mg or more of prednisolone for adults)
* Peripheral blood eosinophil count ≥300cells/μl at initiation of benralizumab treatment and in the year before.
* Obtained reimbursement for treatment with benralizumab
* Provision of signed written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation in the study.
* Patients must be able and willing to read and comprehend written instructions and comprehend and complete the questionnaires required by the protocol.
* Benralizumab naïve and have not previously received benralizumab prior to the start of this study.

Exclusion Criteria

* Patients currently enrolled in an interventional clinical study in parallel (i.e. have not completed) including those with biologic treatment, will be excluded from the study except for patients who are in parallel documented in the Belgian Severe Asthma Registry (BSAR).
* Concurrent biologics for asthma are not allowed except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment. Acceptable wash-out periods for other asthma biologics:
* ≥30 days from last dose of previous biologic
* Patients with other documented lung disease other than asthma and not within reimbursed label.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No